Incretin therapy
Incretin therapy
Understand GLP-1, GIP/GLP-1 and DPP-4 incretin therapies, their uses, differences, benefits and safety considerations.
What is incretin therapy?
Incretin therapy uses medicines that act on gut-hormone pathways involved in blood glucose, appetite and digestion. The two best-known incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), released after eating.
Current treatments include GLP-1 receptor agonists, the dual GIP/GLP-1 agonist tirzepatide and DPP-4 inhibitors, which prolong the action of naturally produced incretins. Products differ in receptor activity, formulation and FDA-approved indication. A diabetes brand is not automatically approved for obesity, even when it contains the same molecule as a weight-management brand.
How incretin pathways work
Glucose-dependent insulin
GLP-1 and GIP signaling can increase insulin release when glucose is elevated, limiting hypoglycemia when used without insulin or a sulfonylurea.
Glucagon signaling
GLP-1 therapies reduce inappropriate glucagon secretion, helping decrease liver glucose output.
Appetite and satiety
GLP-1 and dual agonist medicines can decrease hunger, increase fullness and reduce energy intake.
Gastric emptying
These medicines can slow stomach emptying, particularly early in treatment, affecting symptoms and absorption of oral drugs.
Major incretin-based medication classes
| Class | Examples | Typical role | Weight effect |
|---|---|---|---|
| GLP-1 receptor agonists | Semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide | Type 2 diabetes; certain products also have obesity or cardiovascular indications | Varies by molecule, dose and indication |
| Dual GIP/GLP-1 agonist | Tirzepatide | Type 2 diabetes as Mounjaro; chronic weight management and qualifying OSA as Zepbound | Substantial average loss in obesity trials |
| DPP-4 inhibitors | Sitagliptin, linagliptin, saxagliptin, alogliptin | Type 2 diabetes | Generally weight neutral |
Choosing an incretin treatment
Selection depends on diagnosis, cardiovascular and kidney disease, BMI and complications, glucose goals, gastrointestinal history, pregnancy plans, medication interactions, injection preference, coverage and cost. Treatment should use the product and indication actually prescribed.
Common GLP-1 and tirzepatide effects include nausea, diarrhea, constipation, vomiting and abdominal discomfort. Important precautions include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal disease, diabetic-retinopathy monitoring in some settings, and thyroid C-cell tumor contraindications specified in product labeling.
How W8MD can help
W8MD physicians and clinicians evaluate weight history, medications, nutrition, body composition, metabolic risk factors and sleep-related barriers before recommending an individualized plan. Available services may include medical weight loss, GLP-1 treatment evaluation, established oral medications, nutrition planning, sleep-apnea care and long-term maintenance support.
When an FDA-approved medication is appropriate and insurance coverage exists, W8MD can review benefits and assist with prior-authorization documentation. Coverage and approval are determined by the health plan.
W8MD can compare injectable and oral options, determine whether the goal is diabetes care, obesity treatment, cardiovascular-risk reduction or sleep-apnea care, and coordinate with the patient’s other clinicians. Follow-up includes titration, side-effect management, nutrition, muscle preservation and maintenance planning.
Frequently asked questions
Are all incretin medicines GLP-1 drugs?
No. The category includes GLP-1 agonists, dual agonists and DPP-4 inhibitors, which work differently.
Is tirzepatide stronger than semaglutide?
Average trial results differ, but cross-trial comparisons cannot predict an individual response. Indication, safety, access and tolerability matter.
Can incretin therapy be stopped after reaching goal weight?
Obesity is chronic and regain is common after withdrawal. Any transition should include a maintenance plan.
Authoritative sources
Discuss incretin treatment with W8MD
W8MD Weight Loss, Sleep & MedSpa provides physician-supervised care in Brooklyn, New York and Northeast Philadelphia. Telehealth may be available for eligible patients based on location and applicable requirements.
Contact W8MD
